RecruitingNCT06365905
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
Sponsor
Mayo Clinic
Enrollment
300 participants
Start Date
Mar 27, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.
Eligibility
Sex: FEMALEMin Age: 55 Years
Inclusion Criteria4
- Age ≥ 55 years
- At least one episode of postmenopausal bleeding (PMB)
- Endometrial biopsy available from at Mayo Clinic (MN, AZ, FL), Mayo Clinic Health System (MCHS), or an external institution
- Acceptance to participate in the study
Exclusion Criteria2
- Diagnostic tests performed more than 90 days apart
- Physical impediment/refusal to undergo transvaginal ultrasound (TVUS)
Interventions
OTHERNon-Interventional Study
Non-Interventional Study
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06365905
Related Trials
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225408 locations
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT062534941 location
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT0485111921 locations
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
NCT074079591 location
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT0591926423 locations